Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Sector
Drug Manufacturers - Specialty & Generic
P/S (TTM)
1.4
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.
www.optinose.comNo one on the platform currently holds OPTN.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-03-31 | 12,748 | $116.9K |
| Execution date | Ratio |
|---|---|
| 2024-12-31 | 1-for-15reverse |
No one on the platform has traded OPTN yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 10.2% | 17.7% | ||||
| Profit Margin % | -27.5% | -97.0% | ||||
| Free Cash Flow Margin % | -57.2% | -91.1% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $114M | +13.5% | $-0.97 | $-0.97–$-0.97 | — | 1 |
| 2027 | $137M | +20.3% | $0.23 | $-1.72–$2.17 | 42.7× | 2 |
| 2028 | $184M | +34.6% | $-0.21 | $-0.21–$-0.21 | — | 1 |
| 2029 | $224M | +21.9% | $1.01 | $1.01–$1.01 | 9.5× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2025-05-14 | $-0.74 | $-1.01 | -36.5% |
| 2025-03-26 | $-0.70 | $-0.03 | +95.7% |
| 2024-11-12 | $-0.05 | $0.00 | +105.4% |
| 2024-08-08 | $-1.20 | $-1.05 | +12.5% |
| 2024-05-14 | $-1.50 | $-1.80 | -20.0% |
| 2024-03-07 | $-1.50 | $-1.35 | +10.0% |
| 2023-11-09 | $-1.50 | $-1.20 | +20.0% |
| 2023-08-10 | $-1.65 |
| $0.30 |
| +118.2% |
| $99M |
| — |
| MIROMiromatrix Medical Inc. | $3.39 | +0.59% | $93M | — |
| PROCProcaps Group S.A. | $1.01 | +100.00% | $102M | — |
Source: Financial Modeling Prep · peers by sector/industry
BioVie liver disease carve-out Option Therapeutics decreases shares offered by 20% ahead of $20 million IPO $OPTN $IPO #IPO https://zpr.io
View on StockTwits ↗BioVie liver disease carve-out Option Therapeutics files and sets terms for a $25 million IPO $OPTN $IPO #IPO https://zpr.io/TrJL2VTeaGdx
View on StockTwits ↗
$OPTN Equity Corporate Actions Alert #2025 - 255 Information Regarding the Merger of OptiNose, Inc. (OPTN) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-255 Trading in OPTN epxected to halt at 7:50pm ET tonight. Merger with $PRTK expected to close May 21. Trading in OPTN will be suspended effective May 22. "At a special meeting held on May 16, 2025, the shareholders of OptiNose, Inc. (OPTN) approved the proposed merger with Paratek Pharmaceuticals, Inc. (PRTK) and Orca Merger Sub, Inc., a wholly owned subsidiary of Paratek. The merger is tentatively scheduled to close prior to the market open on May 21, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on May 20, 2025. If the merger closes as anticipated, the stock will remain halted on the day of closing (May 21st) and will be suspended effective May 22, 2025."
View on StockTwits ↗
HC Wainwright & Co. has adjusted their stance on OptiNose ( $OPTN ), setting the rating to Neutral with a target price of 9.
View on StockTwits ↗
WATCHLIST MAY 19 2025. $FYBR Federal Communications Commission Approves Verizon's $20B Acquisition Of Frontier Communications After Verizon Drops Diversity Policies $GIBO GIBO Reveals Upcoming Launch Of GIBO Create-to-Earn Module To Empower Monetization Of AI Animation And Creative Content Within Its Ecosystem $ORCL Oracle Health, Cleveland Clinic, And G42 Announce Strategic Partnership To Develop AI-based Healthcare Delivery Platform $CC Chemours Company Announces Strategic Agreement With DataVolt To Further Demonstrate, Develop Advanced Liquid Cooling Solutions For Data Centers $OPTN HC Wainwright & Co. Reiterates Neutral on OptiNose, Maintains $9 Price Target
View on StockTwits ↗
$OPTN / Paratek Pharmaceuticals – Shareholder Vote $OPTN
View on StockTwits ↗
$OPTN reported - EPS and - revenue for Q1. http://www.estimize.com/intro/optn?chart=historical&metric_name=eps&utm_content=OPTN&utm_medium=
View on StockTwits ↗Wall St is expecting -0.74 EPS for $OPTN Q1 [Reporting 05/15 BMO] http://www.estimize.com/intro/optn?chart=historical&metric_name=eps&utm_c
View on StockTwits ↗
$OPTN "Heads up alert! Only one day until Upcoming earnings on 5/12/2025 for $OPTN Consensus Signal: Bullish (8.3) In the analysis of OptiNose (OPTN), recent performance metrics showcase a company with a promising growth trajectory. For the fourth quarter of 2024, OPTN reported a narrower-than-expected loss of $360,000, indicating a significant earnings surprise of 95.71%. This is a positive indicator, especially against the backdrop of revenue figures that topped estimates by 5.57%, with reported net revenues of $22.4 million for the quarter and $78.2 million for the full year. The 13% increase in net revenue for XHANCE and a robust 23% growth in prescriptions from Q3 to Q4 highlight strong product demand and market penetration. The P/E ratio remains a critical metric for comparison, and while specific figures may vary, the positive earnings revisions suggest an optimistic outlook. Analysts project a substantial upside potential of 143.06% based on average price targets, reflecting confidence in the stock's future performance. Overall, these metrics signal a company well-positioned for growth in the competitive pharmaceutical landscape. Upcoming earnings reports are anticipated to provide further insights, with analysts closely examining the potential impacts of recent operational highlights on future profitability. Historical performance has shown a consistent improvement in revenue and prescription growth, leading to a consensus estimate that supports a positive outlook. The upcoming earnings call will likely focus on strategic initiatives to sustain momentum and address any operational challenges. Analysts recommend closely monitoring these developments, as they could significantly influence investor sentiment and the stock's price trajectory in the near term. - Funds were net sellers of $OPTN during the previous reporting quarter. - Top 3 funds with large holdings in $OPTN: * Nantahala Capital Management LLC $7MM. CGMFundRank: 66%, Fund Website: www.nantahalapartners.com * Stonepine Capital Management LLC $4MM. CGMFundRank: 73%, Fund Website: www.stonepinecap.com * Great Point Partners LLC $2MM. CGMFundRank: 63%, Fund Website: www.gppfunds.com - Last 10 days performance: 1% - Last 30 days performance: 3% - Last 90 days performance: 57% Follow ChessGM on stocktwits.com to get timely earnings alerts. Not a financial advice. Not a trading signal.
View on StockTwits ↗
$OPTN Super positive merger they all should be this way ! LSEG Stocks Plus Report Latest Report 04/24/2025 LSEG maintains a current price target of $18 for OPTN https://archive.fast-edgar.com/20250423/ABBOI62C8W22GZZZ272N2ZZZRMDLZ2V2Z272/
View on StockTwits ↗$OPTN LSEG Stocks Plus Report Latest Report 04/22/2025 LSEG maintains a current price target of $18 for OPTN
View on StockTwits ↗$OPTN Latest Report 04/13/2025 LSEG maintains a current price target of $18 for OPTN
View on StockTwits ↗$OPTN Latest Report 04/10/2025 LSEG maintains a current price target of $18 for OPTN
View on StockTwits ↗$OPTN Latest Report 04/04/2025 LSEG maintains a current price target of $18 for OPTN
View on StockTwits ↗
$OPTN A read of the proxy shows they turned down $15-$20 per share deals while they knew their numbers were coming down only to refinance and dilute to buy themselves time just to give up and sell for a 30-40% discount to prior offers months later....jeeeez
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.